Cargando…

Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study

IMPORTANCE: Patients with vitiligo often have impaired quality of life (QOL) and experience substantial psychosocial burden. OBJECTIVE: To explore the global association of vitiligo with QOL and mental health from the patient perspective. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bibeau, Kristen, Ezzedine, Khaled, Harris, John E., van Geel, Nanja, Grimes, Pearl, Parsad, Davinder, Tulpule, Mukta, Gardner, Jackie, Valle, Yan, Tlhong Matewa, Gaone, LaFiura, Christine, Lindley, Anouk, Ren, Haobo, Hamzavi, Iltefat H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469285/
https://www.ncbi.nlm.nih.gov/pubmed/37647073
http://dx.doi.org/10.1001/jamadermatol.2023.2787
_version_ 1785099408763781120
author Bibeau, Kristen
Ezzedine, Khaled
Harris, John E.
van Geel, Nanja
Grimes, Pearl
Parsad, Davinder
Tulpule, Mukta
Gardner, Jackie
Valle, Yan
Tlhong Matewa, Gaone
LaFiura, Christine
Lindley, Anouk
Ren, Haobo
Hamzavi, Iltefat H.
author_facet Bibeau, Kristen
Ezzedine, Khaled
Harris, John E.
van Geel, Nanja
Grimes, Pearl
Parsad, Davinder
Tulpule, Mukta
Gardner, Jackie
Valle, Yan
Tlhong Matewa, Gaone
LaFiura, Christine
Lindley, Anouk
Ren, Haobo
Hamzavi, Iltefat H.
author_sort Bibeau, Kristen
collection PubMed
description IMPORTANCE: Patients with vitiligo often have impaired quality of life (QOL) and experience substantial psychosocial burden. OBJECTIVE: To explore the global association of vitiligo with QOL and mental health from the patient perspective. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study of the cross-sectional population-based Vitiligo and Life Impact Among International Communities (VALIANT) study was conducted from May 6, 2021, to June 21, 2021. Potential participants for this qualitative study were recruited from an online panel in 17 countries. Of 5859 surveyed adults (aged ≥18 years) who reported a vitiligo diagnosis, 3919 (66.9%) completed the survey, and 3541 (60.4%) were included in the analysis. EXPOSURES: Patients were asked questions regarding their emotional well-being, including QOL and mental health. MAIN OUTCOMES AND MEASURES: Reported analyses are descriptive and hypothesis generating. Vitiligo Impact Patient scale (VIPs) scores ranged from 0 to 60, with higher scores indicating more psychosocial burden. RESULTS: The median age of the 3541 patients was 38 years (range, 18-95 years), and 1933 (54.6%) were male; 1602 patients (45.2%) had more than 5% affected body surface area (BSA; Self-Assessment Vitiligo Extent Score assessed), and 1445 patients (40.8%) had Fitzpatrick skin types IV to VI (ie, darker skin). The mean (SD) global short-form VIPs score was 27.3 (15.6) overall; patients from India (mean [SD], 40.2 [14.1]) reported the highest scores (ie, most burden). The QOL burden according to the scale was profound for patients with more than 5% affected BSA (mean [SD] score, 32.6 [14.2]), darker skin (mean [SD] score, 31.2 [15.6]), and lesions on the face (mean [SD] score, 30.0 [14.9]) or hands (mean [SD], 29.2 [15.2]). At least 40% of patients globally reported that vitiligo frequently affected aspects of their daily lives, including choosing clothes to wear (1956 of 3541 [55.2%]). Most patients (2103 of 3541 [59.4%]) reported concealing their vitiligo frequently. More than half of patients (2078 of 3541 [58.7%]) reported diagnosed mental health conditions, including anxiety (1019 of 3541 [28.8%]) and depression (866 of 3541 [24.5%]). The Patient Health Questionnaire–9 depression screener showed that 55.0% of patients (1948 of 3541) had moderate to severe depressive symptoms; the highest rates were in India (271 of 303 [89.4%]) and among patients with more than 5% affected BSA (1154 of 1602 [72.0%]) and darker skin (987 of 1445 [68.3%]). CONCLUSIONS AND RELEVANCE: This qualitative study found that, globally, patients with vitiligo reported being substantially affected in their emotional well-being, daily lives, and psychosocial health; the burden was typically greatest among patients with more than 5% affected BSA, darker skin types, and lesions on the face or hands. Survey findings suggest that patients reported having altered their behavior, expressed clear discontent, and have symptoms consistent with depression, which may be underdiagnosed.
format Online
Article
Text
id pubmed-10469285
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-104692852023-09-01 Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study Bibeau, Kristen Ezzedine, Khaled Harris, John E. van Geel, Nanja Grimes, Pearl Parsad, Davinder Tulpule, Mukta Gardner, Jackie Valle, Yan Tlhong Matewa, Gaone LaFiura, Christine Lindley, Anouk Ren, Haobo Hamzavi, Iltefat H. JAMA Dermatol Brief Report IMPORTANCE: Patients with vitiligo often have impaired quality of life (QOL) and experience substantial psychosocial burden. OBJECTIVE: To explore the global association of vitiligo with QOL and mental health from the patient perspective. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study of the cross-sectional population-based Vitiligo and Life Impact Among International Communities (VALIANT) study was conducted from May 6, 2021, to June 21, 2021. Potential participants for this qualitative study were recruited from an online panel in 17 countries. Of 5859 surveyed adults (aged ≥18 years) who reported a vitiligo diagnosis, 3919 (66.9%) completed the survey, and 3541 (60.4%) were included in the analysis. EXPOSURES: Patients were asked questions regarding their emotional well-being, including QOL and mental health. MAIN OUTCOMES AND MEASURES: Reported analyses are descriptive and hypothesis generating. Vitiligo Impact Patient scale (VIPs) scores ranged from 0 to 60, with higher scores indicating more psychosocial burden. RESULTS: The median age of the 3541 patients was 38 years (range, 18-95 years), and 1933 (54.6%) were male; 1602 patients (45.2%) had more than 5% affected body surface area (BSA; Self-Assessment Vitiligo Extent Score assessed), and 1445 patients (40.8%) had Fitzpatrick skin types IV to VI (ie, darker skin). The mean (SD) global short-form VIPs score was 27.3 (15.6) overall; patients from India (mean [SD], 40.2 [14.1]) reported the highest scores (ie, most burden). The QOL burden according to the scale was profound for patients with more than 5% affected BSA (mean [SD] score, 32.6 [14.2]), darker skin (mean [SD] score, 31.2 [15.6]), and lesions on the face (mean [SD] score, 30.0 [14.9]) or hands (mean [SD], 29.2 [15.2]). At least 40% of patients globally reported that vitiligo frequently affected aspects of their daily lives, including choosing clothes to wear (1956 of 3541 [55.2%]). Most patients (2103 of 3541 [59.4%]) reported concealing their vitiligo frequently. More than half of patients (2078 of 3541 [58.7%]) reported diagnosed mental health conditions, including anxiety (1019 of 3541 [28.8%]) and depression (866 of 3541 [24.5%]). The Patient Health Questionnaire–9 depression screener showed that 55.0% of patients (1948 of 3541) had moderate to severe depressive symptoms; the highest rates were in India (271 of 303 [89.4%]) and among patients with more than 5% affected BSA (1154 of 1602 [72.0%]) and darker skin (987 of 1445 [68.3%]). CONCLUSIONS AND RELEVANCE: This qualitative study found that, globally, patients with vitiligo reported being substantially affected in their emotional well-being, daily lives, and psychosocial health; the burden was typically greatest among patients with more than 5% affected BSA, darker skin types, and lesions on the face or hands. Survey findings suggest that patients reported having altered their behavior, expressed clear discontent, and have symptoms consistent with depression, which may be underdiagnosed. American Medical Association 2023-08-30 2023-10 /pmc/articles/PMC10469285/ /pubmed/37647073 http://dx.doi.org/10.1001/jamadermatol.2023.2787 Text en Copyright 2023 Bibeau K et al. JAMA Dermatology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License.
spellingShingle Brief Report
Bibeau, Kristen
Ezzedine, Khaled
Harris, John E.
van Geel, Nanja
Grimes, Pearl
Parsad, Davinder
Tulpule, Mukta
Gardner, Jackie
Valle, Yan
Tlhong Matewa, Gaone
LaFiura, Christine
Lindley, Anouk
Ren, Haobo
Hamzavi, Iltefat H.
Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
title Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
title_full Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
title_fullStr Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
title_full_unstemmed Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
title_short Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study
title_sort mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global valiant study
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469285/
https://www.ncbi.nlm.nih.gov/pubmed/37647073
http://dx.doi.org/10.1001/jamadermatol.2023.2787
work_keys_str_mv AT bibeaukristen mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT ezzedinekhaled mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT harrisjohne mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT vangeelnanja mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT grimespearl mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT parsaddavinder mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT tulpulemukta mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT gardnerjackie mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT valleyan mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT tlhongmatewagaone mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT lafiurachristine mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT lindleyanouk mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT renhaobo mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy
AT hamzaviiltefath mentalhealthandpsychosocialqualityoflifeburdenamongpatientswithvitiligofindingsfromtheglobalvaliantstudy